Medisafe Launches New Program, Mediscoveries, Providing Unique Insight Into Medication Management Performance

ORLANDO, FL – February 12, 2019. Medisafe, the leading medication management platform with over five and a half million registered users, announced today a new program providing insights into medicine management behaviors and drug efficacy called Mediscoveries.

For over six years Medisafe has amassed proprietary data on medication adherence on over two billion successful medication doses.  This self-reported aggregated data provides exclusive insight into consumer behaviors such as actual dosing schedules, reasons for skipping, switching patterns and overall adherence and persistence patterns to impact:

  • Consumption patterns
  • Needed treatment interventions
  • Competitive benchmarking

“Medisafe is uniquely positioned to provide consumer driven insights into medication adherence and its impact,” says Omri Shor, CEO and Founder of Medisafe.  “Our Mediscoveries program deep dives into the data to link real-time actual consumer medication consumption and overall medication management implications. 50% of medications are typically not taken as prescribed, so delivering this information to the healthcare eco-system is critical for managing cost, quality and medication effectiveness.”

In the coming months, Medisafe will continue to share Mediscoveries across therapeutic areas.

The Medisafe team will be available at HIMSS 2019 at booth #4224 to share our ground breaking Mediscoveries around an Asthma brand.  To schedule a meeting please click here.

 

Contact:
Jennifer Butler, Chief Marketing Officer
617-650-1390

 

 

You may also like

PDURS: 7 Experts to Follow As the Draft FDA Guidelines Progress

Want to keep current on the FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS)? Follow the LinkedIn profiles 

..Read More

PDURS: What Four Top Law Firms Are Saying

The FDA’s draft guidelines for Prescription Drug Use Related Software (PDURS) have drawn significant attention from the legal community. Law 

..Read More

PDURS: How 7 Companies and Groups Responded to the Draft Guidelines

The FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS) have sparked considerable discussion among various stakeholders, including pharmaceutical 

..Read More

Want to Learn More?

We bring decades of experience to your challenges—and technology and solutions uniquely designed to meet your needs.